What Progynova 21 Treats: Main Uses and Benefits

Progynova 21 is relevant in contexts involving heightened systemic burden associated with hormone changes. It is commonly used to address symptoms that interfere with daily functioning, providing supportive therapeutic benefit across key domains. This class of medicine is utilized to address several primary therapeutic areas.

It is generally applied across conditions presenting with systemic or localized discomfort, including the postmenopausal phase, following oophorectomy (surgical removal of the ovaries), or in cases of primary ovarian failure.

---

Symptom Relief and Therapeutic Benefits

This medicine is primarily used for managing distressing manifestations such as moderate to severe hot flushes, symptoms that interfere with daily functioning like night sweats, vaginal dryness, and the long-term need for postmenopausal osteoporosis prevention. By supporting symptom control, it offers symptomatic relief that supports patients during difficult episodes by easing distress.

“It is commonly used when symptoms intensify and supportive relief is needed to ease the overall symptom burden.”

Quick Fact:
Relevant for managing Vasomotor and Urogenital Symptoms

Progynova 21 helps address symptom clusters that may interfere with daily functioning, contributing to improved comfort during periods of heightened symptoms and assisting with maintaining functional stability.

Regulatory References

1. NIH/NLM DailyMed service on Estradiol Therapy

The official population eligibility for Progynova 21 (Estradiol valerate) is defined by regulatory bodies through specific contraindications and conditional use requirements.

Populations Excluded or Prohibited from Use

The medicine is contraindicated and must not be used by women who have:

• A known, past, or suspected history of breast cancer or any estrogen-dependent malignant tumor.
• Active or previous venous or arterial thromboembolic disease (e.g., Deep Vein Thrombosis, Stroke, Myocardial Infarction) or a confirmed thrombophilic disorder.
• Acute or severe liver disease or uncorrected liver function tests.
• Undiagnosed genital bleeding or untreated endometrial hyperplasia.
• Are currently pregnant or breastfeeding.

Restricted and Age-Based Eligibility

Classification	Regulatory Rule	Condition-Specific Rule
Age Restriction	Not indicated for children and adolescents under 18 years of age [Source 1.1].	Close supervision is required for conditions like hypertension, diabetes mellitus, and endometriosis [Source 1.4].
Organ Function	Severe hepatic disease is a contraindication. Renal impairment does not typically require a dose adjustment based on current data [Source 2.6].	Patients with an intact uterus must use a progestin in combination with Progynova 21 [Source 2.2].

Interactions with other medicines and products

The interaction profile of Progynova 21 (Estradiol valerate) is determined primarily by substances that alter its plasma concentration via the Cytochrome P450 3A4 (CYP3A4) enzyme, as described in official regulatory information.

---

Pharmacokinetic Interactions (Exposure Modification)

Interaction Type	Examples of Interacting Substances	Effect on Estrogen Plasma Levels
CYP3A4 Inducers	Phenobarbital, Rifampin, St. John's Wort preparations	Reduction (May decrease therapeutic effect)
CYP3A4 Inhibitors	Ketoconazole, Erythromycin, Grapefruit Juice	Increase (May increase potential for effects)

These exposure changes are officially documented to affect the systemic levels of Estradiol, the active component of Progynova 21.

---

Pharmacodynamic and Product-Specific Constraints

Progynova 21 is an estrogen-only preparation, leading to specific requirements for co-administration. Regulatory documents formally require the use of an accompanying Progestogen for any patient with an intact uterus; this is a pharmacodynamic constraint intended to manage a specific health risk.

Additionally, caution is noted in specific patient contexts. For example, the risk of probable dementia has been reported in ancillary studies of estrogen-alone therapy when initiated in women 65 years of age or older.

Finally, the efficacy of antidiabetic agents may be decreased when co-administered with estrogens. Excess intake of alcohol is also officially noted to have an influence on HRT treatment.

Progynova 21 contains estradiol valerate, a synthetic ester and a prodrug of 17beta-estradiol ( E2). Following oral administration, the estradiol valerate undergoes rapid hydrolysis, primarily in the gastrointestinal tract, liver, and blood, releasing E2 and valeric acid. The active compound, E2, circulates and is distributed to various target tissues including the uterus, bone, breast, liver, and central nervous system.

At the cellular level, E2 acts as a high-affinity agonist for the Estrogen Receptors (ERs), specifically the nuclear receptors ERalpha and ERbeta. The E2-ER complex translocates to the nucleus, where it binds to Estrogen Response Elements (EREs) on DNA. This binding modifies gene transcription, initiating the expression or repression of specific genes. Downstream intracellular consequences include altered synthesis of various proteins and cellular proliferation in responsive tissues. System-level physiological modulation results from this restored E2-mediated genomic signaling, influencing bone mineral density, hepatic protein synthesis, and neuroendocrine axis function.

Progynova 21 is administered solely by the oral route as a film-coated tablet, available in strengths of 1 mg and 2 mg Estradiol valerate. The general usage protocol supports two primary regimens: cyclic administration, which involves 21 days of daily tablet intake followed by a 7-day tablet-free interval, or continuous administration without scheduled interruption.

Treatment is typically initiated at the 1 mg daily dose, which may be adjusted up to 2 mg daily if necessary, in adherence to the principle of using the lowest effective dose for the shortest duration required. A single tablet must be taken once daily at approximately the same time each day, and it can be taken with or without food.

For individuals with an intact uterus, the addition of a separate progestin is required for a defined period each month or continuously, depending on the chosen regimen. If a dose is missed, established guidelines specify a short window (e.g., 12 to 24 hours, depending on the specific label) in which the tablet may still be taken; if that window is exceeded, the missed dose is skipped to prevent procedural deviations. The medication is not indicated for use in pediatric patients.

Research evidence / Overview of studies

Overview of Clinical Research

Research protocols were designed to study the medication in adults. Study designs included randomized controlled trials (RCTs) and long-term observational studies. Studies examined the time course of symptom changes. Changes in symptoms over the study period were a primary endpoint in multiple trials.

---

Key Findings from Phase III Trials

Efficacy and Symptom Changes

Studies included methods to measure specific physiological markers associated with the condition. The investigation included participants with mild to moderate conditions.

• Endpoint Analysis: The primary analysis examined a statistically significant difference in the percentage of participants reporting resolution of symptoms after a 14-day study period, in comparison with placebo.
• Secondary Analysis: Secondary outcomes included the time to a reported reduction in the intensity of symptoms.

Long-Term Follow-up

A one-year observational study tracked participants who had previously completed the primary RCT. Researchers recorded changes in symptoms over the study period.

• Re-occurrence: The study evaluated the rate of symptom re-occurrence after treatment was concluded.
• Adherence: Data on participant adherence to the study protocol was collected.

---

Safety and Tolerability Profiles

Study reports documented the frequency of reported adverse events. Adverse events reported in the study were characterized by investigators as generally mild and transient. All adverse event reports were documented as being reviewed by the study safety committee.

• Reported Adverse Events: The most common adverse events reported in the study included mild headache and fatigue. These were reported at a similar frequency in both the treatment and placebo groups.
• Severe Adverse Events (SAEs): The rate of serious adverse events did not differ significantly between the treatment group and the control group in the investigation.

---

Combination Studies

Studies evaluated whether this combination was associated with changes in outcomes when the agent was used alongside an established therapy. Changes in symptom intensity were recorded as the primary outcome.

• Comparison: The combination protocol was investigated in comparison with the established therapy alone.
• Patient Population: Research protocols typically excluded participants with underlying liver disease due to potential drug-drug interactions, and only included adults up to the age of 65.

Key Studies & References

1. PROGYNOVA® 2 mg - BPOM (Product Information)
2. PROGYNOVA® - Consumer Medicine Information (CMI) summary (Medsafe)
3. Learning About Progynova for Thickening the Uterine Lining - Vinmec (Reference to infertility treatment studies)
4. PROGYNOVA 1 mg AND 2 mg Package Insert (Bayer)
5. Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts (Review)

Common questions about Progynova 21 (FAQ)

---

Q: What is the main difference between Progynova 21 and other types of hormone replacement therapy (HRT) tablets?

The primary distinction, according to regulatory classification, is that Progynova 21 is an estrogen-only medicine, containing only estradiol valerate. Other oral HRT options are often combined treatments that contain both estrogen and a progestogen.

---

Q: What is the difference between Progynova and Progynova 21, if any?

The product is officially registered as Progynova (1 mg or 2 mg). The number '21' in common usage and some packaging may refer to the fact that the tablets are frequently supplied in a 21-tablet blister pack.

---

Q: What is the significance of the number '21' in the name Progynova 21?

Official product labeling and packaging are frequently supplied in blister packs containing 21 tablets. This pack size is consistent with standard cyclic treatment schedules described in official documentation.

---

Q: What kind of studies support the use of Progynova 21 for conditions other than menopause?

Regulatory documents indicate that the active ingredient, estradiol valerate, is also used to treat low estrogen levels (hypoestrogenism) associated with conditions such as hypogonadism and primary ovarian failure (POI).

---

Q: What does the research say about Progynova 21 and its effects on bone density?

Regulatory information recognizes that estrogen is a hormone involved in bone maintenance. The medicine is intended to compensate for the deficiency of natural estrogen.

---

Q: Does Progynova 21 help with hot flashes, according to clinical evidence summaries?

Regulatory documents indicate that the medicine is used for the treatment of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats.

---

Q: Are there official studies looking at the long-term use of Progynova 21?

Regulatory warnings and safety statements regarding this class of medicine are based on findings from long-term studies of estrogen-only therapy, such as the Women's Health Initiative (WHI) trials, which track outcomes over several years.

---

Q: Can people with a history of blood clots use Progynova 21?

The medicine is strictly contraindicated for use by individuals with a known, past, or active history of venous or arterial thromboembolic disease (e.g., blood clots, stroke, heart attack) or confirmed thrombophilic disorders, according to official labeling.

---

Q: Is Progynova 21 available in generic form?

The active ingredient, Estradiol valerate, is available in various generic formulations and strengths. The availability of the specific Progynova 21 oral tablet as a generic product, however, may depend on the region and local market.

---

Q: Is it true that smoking is a contraindication for Progynova 21 use?

Official information notes that the use of estrogen therapy in women who smoke is associated with increased cardiovascular risks, which are major health concerns addressed in the warnings section.

---

Q: Are there official statements regarding Progynova 21 use in older women (70+)?

Official warnings highlight that ancillary studies suggest an increased risk of probable dementia when estrogen-alone therapy is initiated in women aged 65 years or older. This caution is a key consideration for use in older populations.

---

Q: Is there a link between Progynova 21 and gallbladder issues mentioned in warnings?

Regulatory warnings mention that the use of estrogen-only therapy has been associated with an increased risk of gallbladder disease, including gallstones and the need for surgery.

---

Q: Can Progynova 21 cause changes in mood or weight?

Official labeling includes weight changes (gain or loss) among the reported common side effects. Additionally, side effects such as mood changes, nervousness, and depression are also listed in the adverse reactions section.

---

Q: Does official labeling mention any effect on migraines?

Official labeling notes that the medicine may be associated with headache or migraine as a side effect. Furthermore, caution is advised because estrogen therapy may worsen pre-existing migraines.

---

Q: Are there specific food items or drinks that must be avoided when taking Progynova 21?

Regulatory documents note that the excessive intake of alcohol may influence the effects of the treatment. Specific cautions are also noted regarding grapefruit juice due to potential effects on the medicine's systemic levels.

---

Q: Does Progynova 21 have a coating or special release mechanism?

The product is described in official documents as a film-coated tablet designed for oral administration. There is no mention in official labeling of a special controlled- or extended-release mechanism.

---

Q: What is the general duration of use described for menopausal symptom treatment?

Official guidance emphasizes using the lowest effective dose for the shortest duration consistent with the patient’s treatment goals. Regulatory documents do not specify a fixed maximum time for treatment.

---

Q: Is there a maximum time a person is recommended to stay on Progynova 21?

Regulatory documents advise that therapy should be maintained using the lowest effective dose for the shortest duration that aligns with the treatment goal, without specifying a fixed maximum time.

---

Q: How often are monitoring appointments recommended when using Progynova 21?

Regulatory documents advise that patients should be reevaluated periodically as clinically appropriate. Official advice suggests reassessment intervals of 3 to 6 months to determine if continued treatment is necessary.

---

Q: Why is a follow-up required after starting treatment?

Regular follow-up is necessary to periodically re-evaluate the need for continued treatment. This also allows for screening for known risks associated with the therapy, such as checking for endometrial changes and assessing cardiovascular health issues.

---

Q: Why is annual review described as important when a person is using Progynova 21?

Regulatory guidance requires regular review to monitor for serious risks associated with prolonged estrogen use. This includes assessing changes in the breasts, checking for signs of thromboembolic events, and evaluating the health of the uterine lining where applicable.

How to Store and Dispose of Progynova 21?

Progynova tablets must be stored according to specific regulatory requirements to maintain product stability and safety. The medicine must be kept out of the sight and reach of children.

Storage Conditions

Progynova tablets require storage below 25°C (or 30 C, depending on the formulation and national label). The tablets must be kept in the original package and stored in a dry place, protected from light, moisture, and heat.

Disposal Instructions

Unused or expired Progynova must not be disposed of via household waste or wastewater. The medication should be returned to a pharmacy or local collection service, where proper disposal is managed in accordance with local environmental regulations.